NCT02813694: A reported trial by Nabriva Therapeutics AG
This trial has reported on time, in line with the regulations.
Full data
| Full entry on ClinicalTrials.gov | NCT02813694 |
|---|---|
| Title | A Phase 3, Randomized, Double-Blind, Double-Dummy Study to Compare the Efficacy and Safety of Oral Lefamulin (BC 3781) Versus Oral Moxifloxacin in Adults With Community-Acquired Bacterial Pneumonia |
| Results Status | Reported |
| ACT or pACT? | This is what FDAAA officially calls a "probable Applicable Clinical Trial" |
| Start date | Aug. 31, 2016 |
| Completion date | Jan. 31, 2018 |
| Required reporting date | Jan. 31, 2021, midnight |
| Actual reporting date | Aug. 28, 2019 |
| Date last checked at ClinicalTrials.gov | Dec. 12, 2025 |
| Days late | None |